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Introduction 
Prior to 1988, little had been written about the 
benefit to risk ratio of adding heparin anticoag- 
ulation to intravenous thrombolytic therapy for 
patients with evolving myocardial infarction, and 
heparin was considered to be a relatively trivial 
issue in the overall scheme of coronary throm- 
bolysis. In the past 2 years, however, a consid- 
erable body of new data has been derived from 
intensive clinical research, including the largest 
myocardial reperfusion trial thus far completed'.' 
and five smaller randomized, controlled angio- 
graphic Collectively, a major con- 
troversy* has developed without the requisite un- 
equivocal data necessary for its resolution. In this 
article we will review the major findings of these 
studies and discuss a new trial that, in part, is 
intended to provide balance to the heparin con- 
troversy. 
The Gruppo Italian0 per lo Studio della So- 
pravvivenza nell' Infarto Miocardico (GISSI-2) 
trial with the International Study Group ran- 
domly assigned 20,891 patients with acute myo- 
cardial infarction to receive either tissue plas- 
minogen activator (tPA) or streptokinase (SK). '7' 
The trial had a 2 x 2 factorial design, such that 
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an additional random assignment was to give 
either heparin 12 hours after thrombolysis (dose 
of 12,500 U twice daily) or no heparin. All pa- 
tients received 325 mg of aspirin daily. The study 
demonstrated no difference of mortality reduc- 
tion for both thrombolytic agents (30-day mor- 
tality 8.9% for tPA, 8.5% for SK) and no overall 
benefit for heparin (30 day mortality for the hep- 
arin group was 8.5% compared with 8.9% no hep- 
arin). Secondary evaluation of the data demon- 
strates a tendency for benefit for subcutaneous 
heparin with SK (5,186 patients, mortality = 
7.9%) compared without heparin (5,199 patients, 
mortality = 9.2%) but this was not the case for 
tPA (with heparin [N = 5,1671 mortality = 9.2%; 
without heparin [N = 5,1971 mortality = 8.7%). 
Recently, Pet0 and Collins' have pointed out 
that in GISSI-2 there was actually an 11% mor- 
tality reduction for subcutaneous heparin if only 
patients who died after 12 hours are analyzed 
(5.8% vs 5.2% mortality, 2 P < 0.05). Although 
not prespecified, there is rationale for consider- 
ing such an analysis since the heparin therapy did 
not begin until 12 hours. However, as mentioned, 
the predominant benefit, if any, of subcutaneous 
heparin, even after 12 hours, was among the SK 
treated patients. A smaller trial that did not in- 
clude aspirin therapy also demonstrated a reduc- 
tion of hospital mortality for subcutaneous hep- 
arin and SK compared to SK alone (433 patients, 
mortality was 4.6% vs 8.8%, respectively)." 
As far as intravenous heparin and SK, the data 
are relatively limited. For example, there has not 
been a randomized trial with angiography. How- 
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ever, in the large scale International Studies of 
Infarct Survival (ISIS-2) trial, at the discretion of 
the physician investigators an adjunctive heparin 
regimen was frequently opted for with SK ther- 
apy. Although the assignment was not random- 
ized, the 5-week mortality of patients treated with 
SK and aspirin (N = 1,463) was 9.6% compared 
with 7.6% for patients also receiving subcuta- 
neous heparin (N = 1,805), and 6.4% for exten- 
sive therapy with the addition of intravenous hep- 
arin (N = 1,024). These favorable results for SK, 
aspirin, and intravenous heparin were not accom- 
panied by significant increase in stroke or intra- 
cerebral hemorrhagic events. However, the bias 
of administering a more aggressive heparin reg- 
imen to a lower risk group of patients is a possible 
explanation. The overall profile of clinical out- 
comes for intravenous SK and heparin is, none- 
theless, very positive given this rather large data 
set. 
In a relatively short period of time concurrent 
to GISSI-2’s completion, there have been five 
randomized angiographic trials of tPA with or 
without intravenous heparin3-’ as summarized in 
Table 1. The study designs differed in many im- 
portant aspects, particularly the timing of the an- 
giogram, the dose of aspirin, use of a placebo 
heparin, and the sample size. In Thrombolysis 
and Angioplasty in Myocardial Infarction-3 
(TAMI-3)3 the angiogram at 90 minutes was the 
primary end point, and after that time the patients 
not initially receiving intravenous heparin were 
given this therapy. The dose of tPA was 1.25 mg/ 
kg with a maximum of 135 mg, which is higher 
than the currently recommended dose. Of note, 
the first angiogram at 90 minutes demonstrated 
a trend in favor of heparin for infarct vessel pat- 
ency (77% vs 71%), but this trend dissipated by 
the time of the “final” angiogram, which by con- 
vention in TAMI has been up to the fourth in- 
jection to standardize the potential for selective 
contrast injection facilitation of patency. Thus, 
the experimental findings that the fibrinolytic ac- 
tion of tPA is facilitated by intravenous heparin 
may be particularly at a lower dose of 
tPA or with a larger population of patients as- 
sessed using the first angiogram as the primary 
end point. 
The Heparin Aspirin Reperfusion Trial 
(HART)4 demonstrated a large (30 percentage 
point) difference in patency at 18 hours after ran- 
domization. In this trial, only 80 mg of aspirin 
was given without an early dose on presentation. 
Furthermore, a higher proportion of patients with 
right coronary artery infarct vessels were ran- 
domly assigned to the nonheparin group. Bates 
et a1.14 have shown that it is significantly more 
difficult to achieve thrombolysis with the right 
compared with left coronary artery. A smaller 
trial performed by Bleich and  colleague^,^ also 
found a large (27 percentage point) difference in 
patency , at a mean of 40 rather than 18 hours after 
randomization, but no aspirin was given. The re- 
cently completed European Cooperative Study 
Group6 enrolled the largest number of patients 
(N = 644), assessed the patency later (2-5 days, 
average of 80 hours), gave an immediate intra- 
venous aspirin dose and a low alternate day oral 
regimen, and found only an 8 percentage point 
difference in patency. Of particular note, these 
Table 1. 
Patency (%) 
Study N Aspirin Dose* Placebo Time Assessed Heparin No Heparin 
TAMI-33 170 325 mg No 90 min 79 79 
HART4 204 80 mg No 18 hrs 82 52 
Bleich et aL5 83 None No 40 hrs 71 44 
ECSG-66 644 250 mg IV, Yes 80 hrs 83 75 
NHF7.** 24 1 325 mg No 7 days 80 80 
then 
100 mg qod 
ECSG = European Cooperative Study Group; HART = Heparin Aspirin Reperfusion Trial; NHF = National Heart Foundation; 
TAMI = Thrombolysis and Angioplasty in Myocardial Infarction; IV = intravenous; *administered orally daily unless otherwise 
specified; **randomization to heparin or no heparin was after 24 hours of intravenous heparin for all patients. 
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investigators found a direct relationship between 
the activated partial thromboplastin time and 
subsequent patency , further establishing the link 
between antithrombin effect and prevention of 
coronary thrombosis. The results are quite dif- 
ferent in magnitude of heparin effect compared 
with the HART4 and Bleich et aL5 studies. It re- 
mains unclear whether the smaller, albeit statis- 
tically significant, difference in infarct vessel pat- 
ency is due to angiographic assessment at a later 
time, the use of early, higher dose intravenous 
aspirin, or simply a more realistic assessment 
owing to a threefold increase in sample size. 
The other randomized trial of tPA and intra- 
venous heparin was performed by the National 
Heart Foundation of A~s t r a l i a .~  It differed sub- 
stantially from the others because all patients ini- 
tially received 24 hours of intravenous heparin. 
The patients assigned to discontinue heparin 
were instead given daily aspirin and dipyridamole 
and no difference in patency was found at pre- 
discharge evaluation. 
The interpretation of these five trials is subject 
to considerable uncertainty and bias. On the one 
hand, we can definitely conclude that intrave- 
nous heparin helps to maintain infarct vessel pat- 
ency with tPA. The major question that remains, 
however, is to what extent and how does this 
differ from SK, which may similarly benefit from 
coadministration of intravenous heparin. An ad- 
ditional key concern is the comparative risk of 
bleeding complications for these regimens. 
These uncertainties, further stimulated by a 
very aggressive marketing approach by the man- 
ufacturer of tPA,’’ have led to a situation in 
which the results of a major trial have had little 
effect on the choice of thrombolytic agents in the 
United States. With an extraordinarily large sam- 
ple size and adequate statistical power, the 
GISSI-2 and International trial has documented 
tPA and SK equivalency. While the adjunctive 
heparin regimen deserves careful study, the find- 
ings of GISSI-2 are unequivocal until proven 
otherwise. Given the encouraging new data for 
combination thrombolytic therapy (with heparin 
and aspirin),’6-2’ front loaded tPA 
and the frequent clinical practice of administering 
intravenous heparin with thrombolytics, we, in 
collaboration with many other clinical investi- 
gators in the United States and abroad have just 
initiated a 33,600 patient trial with the acronym 
of GUSTO (Global Utilization of Streptokinase 
and tPA for Occluded Coronary Arteries). The 
primary objective of this trial will be to evaluate 
the effects of rapid and sustained infarct vessel 
patency on survival. 
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